Author: Bret Jensen, Biotech Gems

They represent deep value in what is increasingly looking like an overbought market…

I have moved them to heavily overweight within my own portfolio…

They’re undervalued right now, they have growing earnings, and they’ve recently experienced a small decline in share price (giving investors a great opportunity to hop in)…

They’re offering attractive entry points at the moment…